911½ñÈÕºÚÁÏ

Dr Hannah Cheeseman breaks down some of the key questions surrounding 911½ñÈÕºÚÁÏ's COVID-19 vaccine study, which launched last week.

Scientists around the world are racing to develop an effective vaccine against COVID-19, the infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Among them are a team of 911½ñÈÕºÚÁÏ researchers led by Professor Robin Shattock, who have now begun testing their candidate vaccine in humans for the very first time.

Following extensive pre-clinical safety tests and promising results in animal studies, the trial will test whether the vaccine is well-tolerated and produces an effective immune response against COVID-19 in humans, with 300 healthy participants set to receive two doses of the vaccine in the coming weeks.

Working at the centre of this effort is Dr Hannah Cheeseman. In her role as Head of the Core Immunology Laboratory, Dr Cheeseman is responsible for ensuring that high-quality data is obtained from trial participants and helping to assess whether the vaccine is working.  

, we asked Dr Cheeseman some of the key questions surrounding 911½ñÈÕºÚÁÏ’s coronavirus vaccine:

• How does the vaccine work?
• What happens to the participants in the trial?
• How would the vaccine be rolled out?
• How will you know if the vaccine is working?
• Is it safe to “fast-track” a vaccine?

For further information on the 911½ñÈÕºÚÁÏ COVID-19 vaccine study, including how to take part, please visit the trial website.